Home > Boards > US Listed > Biotechs > Cytokinetics, Inc. (CYTK)

New SA article on CYTK

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
H2R Member Profile
 
Followed By 25
Posts 1,833
Boards Moderated 0
Alias Born 07/17/14
160x600 placeholder
Cytokinetics to Participate in Upcoming Investor Conferences GlobeNewswire Inc. - 3/2/2021 4:00:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/1/2021 5:06:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/1/2021 5:05:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/1/2021 5:02:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/1/2021 6:06:59 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/26/2021 6:25:43 PM
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 2/26/2021 4:32:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/26/2021 7:30:58 AM
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day GlobeNewswire Inc. - 2/26/2021 7:30:00 AM
Cytokinetics EPS misses by $0.13, misses on revenue Seeking Alpha - 2/25/2021 4:19:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/25/2021 4:01:19 PM
Cytokinetics Reports Fourth Quarter 2020 Financial Results GlobeNewswire Inc. - 2/25/2021 4:00:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/19/2021 5:03:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/19/2021 4:20:34 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/18/2021 7:30:59 AM
Cytokinetics Names Muna Bhanji to Board of Directors GlobeNewswire Inc. - 2/18/2021 7:30:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 3:17:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/12/2021 6:39:21 PM
Cytokinetics to Announce Fourth Quarter Results on February 25, 2021 GlobeNewswire Inc. - 2/11/2021 4:00:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/10/2021 10:50:19 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/8/2021 10:08:13 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/2/2021 7:30:48 AM
Cytokinetics Announces Recipients of Third Annual Communications Fellowship Grants GlobeNewswire Inc. - 2/2/2021 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/1/2021 4:00:56 PM
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 2/1/2021 4:00:00 PM
H2R   Thursday, 10/26/17 03:18:42 PM
Re: None
Post # of 1503 
New SA article on CYTK

https://seekingalpha.com/article/4116891-cytokinetics-separating-wheat-chaff

Quote:
Biotech investors bear the dual risk of
-drug approval and
-drug market acceptance.

In my opinion, the market risk for Tirasemtiv if approved, is essentially nil. The sales force needed to commercialize the ALS drug need to only be extremely small. It's not a stretch to say that a single rep with a telephone could sell the drug to the majority of ALS treatment providers and patients in the US.



So if approved, we should have a big time winner!

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences